Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of 18F-FDG PET/CT indices on extensive residual cancer burden in breast cancer patients treated with neoadjuvant chemotherapy.
Başoğlu T, Özgüven S, Özkan HŞ, Çınar M, Köstek O, Demircan NC, Arıkan R, Telli TA, Ercelep Ö, Kaya H, Öneş T, Erdil TY, Uğurlu MÜ, Dane F, Yumuk PF. Başoğlu T, et al. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022 May-Jun;41(3):171-178. doi: 10.1016/j.remnie.2021.05.007. Epub 2021 May 26. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2022. PMID: 35577492
How long should we continue crizotinib in ALK translocation-positive inflammatory myofibroblastic tumors? Long-term complete response with crizotinib and review of the literature.
Alan O, Kuzhan O, Koca S, Telli TA, Basoglu T, Ercelep O, Filinte D, Sengul Y, Arikan H, Kaya S, Babacan NA, Dane F, Yumuk PF. Alan O, et al. Among authors: basoglu t. J Oncol Pharm Pract. 2020 Jun;26(4):1011-1018. doi: 10.1177/1078155219879757. Epub 2019 Oct 15. J Oncol Pharm Pract. 2020. PMID: 31615346 Review.
Is insulin resistance a predictor for complete response in breast cancer patients who underwent neoadjuvant treatment?
Alan O, Akin Telli T, Aktas B, Koca S, Ökten IN, Hasanov R, Basoglu T, Arikan R, Demircan NC, Ercelep O, Kaya S, Ugurlu MU, Kaya H, Akgul Babacan N, Dane F, Yumuk PF. Alan O, et al. Among authors: basoglu t. World J Surg Oncol. 2020 Sep 9;18(1):242. doi: 10.1186/s12957-020-02019-y. World J Surg Oncol. 2020. PMID: 32907593 Free PMC article.
Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences.
Tural D, Ölmez ÖF, Sümbül AT, Artaç M, Özhan N, Akar E, Çakar B, Köstek O, Ekenel M, Erman M, Coşkun HŞ, Selçukbiricik F, Keskin Ö, Türköz FP, Oruç K, Bayram S, Yılmaz U, Bilgetekin İ, Yıldız B, Şendur MAN, Paksoy N, Dirican A, Erdem D, Selam M, Tanrıverdi Ö, Paydaş S, Urakçı Z, Atağ E, Güncan S, Ürün Y, Alkan A, Kaya AO, Özyükseler DT, Taşkaynatan H, Yıldırım M, Sönmez M, Başoğlu T, Gündüz Ş, Kılıçkap S. Tural D, et al. Among authors: basoglu t. Eur Urol Focus. 2021 Sep;7(5):1061-1066. doi: 10.1016/j.euf.2020.09.010. Epub 2020 Sep 30. Eur Urol Focus. 2021. PMID: 33008789
Impact of prognostic nutritional index on survival in recurrent glioblastoma.
Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Sakar M, Bozkurt S, Atasoy BM, Dane F, Ziyal Mİ, Yumuk PF. Alan O, et al. Among authors: basoglu t. Neurocirugia (Astur : Engl Ed). 2021 Jan 13:S1130-1473(20)30136-6. doi: 10.1016/j.neucir.2020.11.005. Online ahead of print. Neurocirugia (Astur : Engl Ed). 2021. PMID: 33454185 English, Spanish.
Impact of prognostic nutritional index on survival in recurrent glioblastoma.
Alan O, Telli TA, Basoğlu T, Arikan R, Demircan NC, Ercelep O, Sakar M, Bozkurt S, Atasoy BM, Dane F, Ziyal Mİ, Yumuk PF. Alan O, et al. Among authors: basoglu t. Neurocirugia (Astur : Engl Ed). 2022 Jan-Feb;33(1):15-21. doi: 10.1016/j.neucie.2020.11.004. Neurocirugia (Astur : Engl Ed). 2022. PMID: 34998488
73 results